½ÃÀ庸°í¼­
»óǰÄÚµå
1599624

¿©¼º °Ç°­ Ä¡·á ½ÃÀå : À¯Çüº°, À¯Åë ä³Îº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Women¢¥s Health Therapeutics Market by Type (Infection, Oncology, Pregnancy), Distribution Channel (Drug Stores & Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 190 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

2023³â ¿©¼º °Ç°­ Ä¡·á ½ÃÀå ±Ô¸ð´Â 654¾ï 9,000¸¸ ´Þ·¯·Î 2024³â¿¡´Â 722¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¬Æò±Õ 10.74% ¼ºÀåÇÏ¿© 2030³â¿¡´Â 1,338¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¿©¼º °Ç°­ Ä¡·á ½ÃÀåÀº »ý½Ä °Ç°­, °»³â±â, °ñ´Ù°øÁõ, ƯÁ¤ ÀÚ°¡¸é¿ª Áúȯ, ½ÉÇ÷°üÁúȯ µî ¿©¼º ƯÀ¯ÀÇ Áõ»ó°ú ÁúȯÀ» Ä¡·áÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. ÀÌ ½ÃÀåÀÇ Çʿ伺Àº ¿©¼º ƯÀ¯ÀÇ »ý¸®Àû ¿ä±¸¿¡ ÀÖÀ¸¸ç, ¿©¼º ƯÀ¯ÀÇ »ý¹°ÇÐÀû ±¸Á¶¿¡ ¸ÂÃß¾î ´õ ³ªÀº °Ç°­ °á°ú¸¦ º¸ÀåÇÕ´Ï´Ù. ½ÃÀå ³» ÀÀ¿ë ºÐ¾ß¿¡´Â ÀǾàǰ, »ý¹°ÇÐÀû Á¦Á¦, ±â±â, Áø´Ü ÀǾàǰÀÌ Æ÷ÇԵǸç, ÃÖÁ¾ ¿ëµµ¿¡´Â º´¿ø, Ŭ¸®´Ð, ¼Ò¸Å ¾à±¹, ¿Â¶óÀÎ Ç÷§ÆûÀÌ Æ÷ÇԵ˴ϴÙ. ÁÖ¿ä ¼ºÀå µ¿·ÂÀº ¿©¼º °Ç°­ ¹®Á¦¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ÀÇ·áºñ ÁöÃâ Áõ°¡, »ý¸í°øÇÐ ±â¼úÀÇ ¹ßÀü, ¿©¼º °Ç°­ ÁõÁø¿¡ ´ëÇÑ Á¤ºÎÀÇ Áö¿ø Á¤Ã¥ µîÀÔ´Ï´Ù. ¸ÂÃãÇü ÀÇ·á¿Í °³ÀÎÈ­µÈ ¸ð´ÏÅ͸µ ¹× Ä¡·á¸¦ Á¦°øÇÏ´Â ¿þ¾î·¯ºí ±â±â ¹× ¿ø°ÝÀÇ·á¿Í °°Àº µðÁöÅÐ °Ç°­ ±â¼úÀÇ ÅëÇÕÀº ¸¹Àº ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ±â¾÷µéÀº ¿¬±¸°³¹ß¿¡ ÅõÀÚÇϰí ÷´Ü ±â¼ú ±â¾÷, ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü, °Ç°­ ¿ËÈ£ ´Üü¿ÍÀÇ Á¦ÈÞ¸¦ ÅëÇØ ÀÌ·¯ÇÑ ±âȸ¸¦ Ȱ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº ¿¬±¸ ºñ¿ë, ±ÔÁ¦ À庮, ƯÁ¤ Áö¿ªÀÇ ¿©¼º °Ç°­ ¹®Á¦¿¡ ´ëÇÑ ¹®È­Àû Æí°ß µî ½ÃÀå ¼ºÀå¿¡ °É¸²µ¹ÀÌ µÇ°í ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ħÅõ¿Í ¼ö¿ë¼º ¸ðµÎ¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀϺΠÁö¿ª¿¡¼­´Â »óȯ Á¤Ã¥ ¹× ¼÷·ÃµÈ ÀÇ·á Àü¹®°¡ È®º¸¿¡µµ ÇѰ谡 ÀÖ½À´Ï´Ù. Çõ½Å ³ë·ÂÀº ºñħ½ÀÀû Áø´Ü µµ±¸, »õ·Î¿î ¾à¹° Á¦Á¦, ¿©¼ºÀÇ »ý¾ÖÁֱ⿡ °ÉÄ£ ´Ù¸éÀûÀÎ ¿ä±¸¸¦ ÃæÁ·½ÃŰ´Â Á¾ÇÕÀûÀÎ ÀÇ·á Ç÷§Æû °³¹ß¿¡ ÁßÁ¡À» µÎ¾î¾ß ÇÕ´Ï´Ù. Áö¼ÓÀûÀÎ ±³À° ¹× ÀÎ½Ä °³¼± Ä·ÆäÀÎÀº ±¤¹üÀ§ÇÑ ÀÇ·á °³Çõ¿¡ ¿©¼º °Ç°­À» Æ÷ÇÔ½ÃŰ´Â °Í°ú ¸¶Âù°¡Áö·Î ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ½ÃÀåÀº °úÇÐ, Á¤Ã¥, ¼ÒºñÀÚ ÇൿÀÇ Á¶ÇÕ¿¡ ÀÇÇØ ¿òÁ÷ÀÌ´Â ¿ªµ¿ÀûÀÎ ½ÃÀåÀ̸ç, ¼º°øÇÏ´Â ±â¾÷Àº ÃÖ÷´Ü ¿¬±¸¸¦ Ȱ¿ëÇϰí, Àü·«Àû Á¦ÈÞ¸¦ ¸Î°í, ±ÔÁ¦ ȯ°æÀ» ±Øº¹Çϰí, ÁøÈ­ÇÏ´Â ¼ÒºñÀÚ ±â´ë¿¡ ÀûÀÀÇÒ ¼ö ÀÖ´Â ±â¾÷ÀÏ °ÍÀÔ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 654¾ï 9,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 722¾ï 1,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 1,338¾ï 2,000¸¸ ´Þ·¯
CAGR(%) 10.74%

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â ¿©¼º °Ç°­ Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®¸¦ °ø°³

¿©¼º °Ç°­ Ä¡·á ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¿©¼ºÀÇ ¸¸¼º °Ç°­ »óÅ Áõ°¡
    • ¿©¼º °Ç°­ ¹× ¼º °Ç°­ Çâ»óÀ» À§ÇÑ Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê
    • ºÒÀÓ ¹× °»³â±â Àå¾Ö Ä¡·á Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • °Ç°­º¸Çè ¹Ì°¡ÀÔÀ¸·Î ÀÎÇÑ Ä¡·áºñ Æøµî
  • ½ÃÀå ±âȸ
    • µðÁöÅÐ ¸ÂÃãÇü ÀÇ·á¿Í ÆèÅØÀÇ ºÎ»ó
    • ¿©¼º ƯÀ¯ÀÇ ¹Ìº´ Ä¡·á¸¦ À§ÇÑ ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·áÀÇ ¹ßÀü
  • ½ÃÀå °úÁ¦
    • ´Ù¾çÇÑ Ä¡·á¹ýÀÇ ºÎÀÛ¿ë¿¡ ´ëÇÑ ¿ì·Á

Porter's Five Forces : ¿©¼º °Ç°­ Ä¡·á ½ÃÀå °ø·«À» À§ÇÑ Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲÀÇ °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â µ¥ Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀïÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ¸ð»öÇϱâ À§ÇÑ ¸íÈ®ÇÑ ¹æ¹ýÀ» ¼³¸íÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®¸¦ ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇÏ°í ¾àÁ¡À» º¸¿ÏÇϸç ÀáÀçÀû µµÀüÀ» ÇÇÇÔÀ¸·Î½á º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¿©¼º °Ç°­ Ä¡·á ½ÃÀå¿¡¼­ÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¿©¼º °Ç°­ Ä¡·á ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ ´ã°í ÀÖÀ¸¸ç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀ̰í Àû±ØÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ¿©¼º °Ç°­ Ä¡·á ½ÃÀå¿¡¼­ °æÀï ±¸µµ ÆÄ¾Ç

¿©¼º °Ç°­ Ä¡·á ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ¼¼ºÐÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÏ¿© °ø±Þ¾÷ü°¡ Ä¡¿­ÇÑ °æÀï¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ¿©¼º °Ç°­ Ä¡·á ½ÃÀå¿¡¼­ º¥´õÀÇ ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¿©¼º °Ç°­ Ä¡·á ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ : ¿©¼º °Ç°­ Ä¡·á ½ÃÀå¿¡¼­ ¼º°øÀÇ ±æÀ» ±×¸³´Ï´Ù.

¿©¼º °Ç°­ Ä¡·á ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ ü°è¸¦ ±¸ÃàÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÎ¹®¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·ÂÀ» Æò°¡ÇÕ´Ï´Ù.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÎ¹®ÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» ±â¼úÇϰí ÀÖ½À´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, »ê¾÷ÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ÇâÈÄ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ, ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ¿©¼º °Ç°­ Ä¡·á ½ÃÀå : À¯Çüº°

  • ¼Ò°³
  • °¨¿°
  • Á¾¾ç
    • ÀڱðæºÎ¾Ï
    • ³­¼Ò¾Ï
    • ÀڱþÏ
  • ÀÓ½Å
  • Áú¾Ï°ú ¿ÜÀ½ºÎ¾Ï

Á¦7Àå ¿©¼º °Ç°­ Ä¡·á ½ÃÀå : À¯Åë ä³Îº°

  • ¼Ò°³
  • µå·°½ºÅä¾î¿Í ¾à±¹
  • º´¿ø ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦8Àå ¾Æ¸Þ¸®Ä«ÀÇ ¿©¼º °Ç°­ Ä¡·á ½ÃÀå

  • ¼Ò°³
  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¿©¼º °Ç°­ Ä¡·á ½ÃÀå

  • ¼Ò°³
  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦10Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¿©¼º °Ç°­ Ä¡·á ½ÃÀå

  • ¼Ò°³
  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®
  • ¿µ±¹

Á¦11Àå °æÀï »óȲ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023³â
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Abbott Laboratories
  • AbbVie Inc.
  • Agile Therapeutics Inc.
  • Amgen Inc.
  • Bayer AG
  • F. Hoffmann La Roche Ltd.
  • Ferring B.V.
  • GLS Pharma Pvt. Ltd.
  • Mithra Pharmaceuticals SA.
  • Novartis AG
  • Novo Nordisk AS
  • ObsEva SA
  • Pfizer Inc.
  • Radius Health Inc.
  • Sanofi SA
ksm 24.12.04

The Women's Health Therapeutics Market was valued at USD 65.49 billion in 2023, expected to reach USD 72.21 billion in 2024, and is projected to grow at a CAGR of 10.74%, to USD 133.82 billion by 2030.

The Women's Health Therapeutics market focuses on treatments addressing conditions and diseases unique to or more prevalent in women, encompassing reproductive health, menopause, osteoporosis, and certain autoimmune and cardiovascular diseases. The necessity of this market lies in the demographic's specific physiological needs, ensuring better health outcomes tailored to women's unique biological makeup. Applications within the market include pharmaceuticals, biologics, devices, and diagnostics, with end-use scope covering hospitals, clinics, retail pharmacies, and online platforms. Key growth drivers include rising awareness of women's health issues, increased healthcare expenditure, advancements in biotechnology, and supportive governmental policies promoting women's health initiatives. Opportunities abound in personalized medicine and the integration of digital health technologies like wearable devices and telemedicine, which offer personalized monitoring and treatment. Companies can capitalize on these opportunities by investing in R&D and partnerships with tech firms, healthcare providers, and health advocacy groups. However, market growth faces challenges such as high research costs, regulatory barriers, and cultural stigma around women-specific health issues in certain regions, affecting both market penetration and acceptance. Additionally, there are limitations in reimbursement policies and the availability of skilled healthcare professionals in some areas. Innovation efforts should pivot towards developing non-invasive diagnostic tools, novel drug formulations, and comprehensive healthcare platforms that address multifaceted needs across a woman's life cycle. Continuous education and awareness campaigns are crucial, as is the inclusion of women's health in broader healthcare reforms. The market is dynamic, driven by a combination of science, policy, and consumer behavior, where successful players will be those who can leverage cutting-edge research, form strategic alliances, and adapt to evolving consumer expectations while navigating regulatory environments.

KEY MARKET STATISTICS
Base Year [2023] USD 65.49 billion
Estimated Year [2024] USD 72.21 billion
Forecast Year [2030] USD 133.82 billion
CAGR (%) 10.74%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Women's Health Therapeutics Market

The Women's Health Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing incidence of chronic health conditions among women
    • Government initiatives to improve women's health and sexual wellness
    • Increasing prevalence of infertility and menopausal treatments
  • Market Restraints
    • High cost of treatment due to lack of health insurance
  • Market Opportunities
    • Rise in digital personalized healthcare and femtech
    • Advances in cell and gene therapy to treat underserved female-specific conditions
  • Market Challenges
    • Concerns related to side-effects of various therapies

Porter's Five Forces: A Strategic Tool for Navigating the Women's Health Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Women's Health Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Women's Health Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Women's Health Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Women's Health Therapeutics Market

A detailed market share analysis in the Women's Health Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Women's Health Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Women's Health Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Women's Health Therapeutics Market

A strategic analysis of the Women's Health Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Women's Health Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Agile Therapeutics Inc., Amgen Inc., Bayer AG, F. Hoffmann La Roche Ltd., Ferring B.V., GLS Pharma Pvt. Ltd., Mithra Pharmaceuticals SA., Novartis AG, Novo Nordisk AS, ObsEva SA, Pfizer Inc., Radius Health Inc., and Sanofi SA.

Market Segmentation & Coverage

This research report categorizes the Women's Health Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Infection, Oncology, Pregnancy, and Vaginal & Vulvar Cancer. The Oncology is further studied across Cervical Cancer, Ovarian Cancer, and Uterine Cancer.
  • Based on Distribution Channel, market is studied across Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidence of chronic health conditions among women
      • 5.1.1.2. Government initiatives to improve women's health and sexual wellness
      • 5.1.1.3. Increasing prevalence of infertility and menopausal treatments
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment due to lack of health insurance
    • 5.1.3. Opportunities
      • 5.1.3.1. Rise in digital personalized healthcare and femtech
      • 5.1.3.2. Advances in cell and gene therapy to treat underserved female-specific conditions
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns related to side-effects of various therapies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Women's Health Therapeutics Market, by Type

  • 6.1. Introduction
  • 6.2. Infection
  • 6.3. Oncology
    • 6.3.1. Cervical Cancer
    • 6.3.2. Ovarian Cancer
    • 6.3.3. Uterine Cancer
  • 6.4. Pregnancy
  • 6.5. Vaginal & Vulvar Cancer

7. Women's Health Therapeutics Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Drug Stores & Retail Pharmacies
  • 7.3. Hospital Pharmacies
  • 7.4. Online Pharmacies

8. Americas Women's Health Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Women's Health Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Women's Health Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Agile Therapeutics Inc.
  • 4. Amgen Inc.
  • 5. Bayer AG
  • 6. F. Hoffmann La Roche Ltd.
  • 7. Ferring B.V.
  • 8. GLS Pharma Pvt. Ltd.
  • 9. Mithra Pharmaceuticals SA.
  • 10. Novartis AG
  • 11. Novo Nordisk AS
  • 12. ObsEva SA
  • 13. Pfizer Inc.
  • 14. Radius Health Inc.
  • 15. Sanofi SA
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦